Activators and inhibitors of protein kinase c (Pkc): Their applications in clinical trials

Takahito Kawano, Junichi Inokuchi, Masatoshi Eto, Masaharu Murata, Jeong Hun Kang

研究成果: Contribution to journalReview article査読

抄録

Protein kinase C (PKC), a family of phospholipid-dependent serine/threonine kinase, is classed into three subfamilies based on their structural and activation characteristics: conventional or classic PKC isozymes (cPKCs; α, βI, βII, and γ), novel or non-classic PKC isozymes (nPKCs; δ, ε, η, and θ), and atypical PKC isozymes (aPKCs; ζ, ι, and λ). PKC inhibitors and activators are used to understand PKC-mediated intracellular signaling pathways and for the diagnosis and treatment of various PKC-associated diseases, such as cancers, neurological diseases, cardiovascular diseases, and infections. Many clinical trials of PKC inhibitors in cancers showed no significant clinical benefits, meaning that there is a limitation to design a cancer therapeutic strategy targeting PKC alone. This review will focus on the activators and inhibitors of PKC and their applications in clinical trials.

本文言語英語
論文番号1748
ジャーナルPharmaceutics
13
11
DOI
出版ステータス出版済み - 11 2021

All Science Journal Classification (ASJC) codes

  • 薬科学

フィンガープリント

「Activators and inhibitors of protein kinase c (Pkc): Their applications in clinical trials」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル